Visit Company Website: www.agitherapeutics.com
View Company News: See Articles
AGI is a specialty pharmaceutical company that focused on the development and commercialisation of differentiated specialty drug products to treat unmet medical needs, in Gastroenterology
and conditions which qualify for Orphan drug status. Following venture funding led by ACT, AGI completed a successful IPO in 2006, raising €42m.
In February, 2012, AGI Therapeutics was acquired by Aravis Limited, a member of the Vidara Therapeutics group of companies. Following the acquisition, on March 2nd, 2012, AGI de-listed from the Alternative Investment Market of the London Stock Exchange (AIM) and the Enterprise Securities Market of the Irish Stock Market (ESM).